Virpax Pharmaceuticals, Inc. short interest in 2023
In 2023, Virpax Pharmaceuticals, Inc.'s disclosed short interest ran from 0.29% of shares outstanding on 13 Jan 2023 to 0.14% on 15 Dec 2023, a change of -0.15 percentage points. The year's high was 0.90% on 15 May 2023 and its low 0.14% on 15 Sep 2023, averaging 0.47% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.66 days on 28 Apr 2023. Full history: Virpax Pharmaceuticals, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024
2023 in figures
- Start of year
- 0.29% (13 Jan 2023)
- End of year
- 0.14% (15 Dec 2023)
- Change
- -0.15 pp
- High
- 0.90% (15 May 2023)
- Low
- 0.14% (15 Sep 2023)
- Average
- 0.47%
- Highest days to cover
- 6.66 (28 Apr 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.29% | 1.00 | |
| 31 Jan 2023 | 0.29% | 1.00 | |
| 28 Feb 2023 | 0.68% | 2.62 | |
| 15 Mar 2023 | 0.72% | 5.18 | |
| 31 Mar 2023 | 0.78% | 5.31 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 0.72% | 4.96 | |
| 28 Apr 2023 | 0.74% | 6.66 | |
| 15 May 2023 | 0.90% | 4.77 | 10-Q filed, results (8-K) |
| 31 May 2023 | 0.66% | 5.00 | |
| 15 Jun 2023 | 0.43% | 1.70 | |
| 30 Jun 2023 | 0.68% | 1.00 | |
| 14 Jul 2023 | 0.35% | 1.77 | |
| 31 Jul 2023 | 0.36% | 1.93 | |
| 15 Aug 2023 | 0.29% | 1.39 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 0.22% | 1.19 | |
| 15 Sep 2023 | 0.14% | 1.00 | |
| 13 Oct 2023 | 0.24% | 1.00 | |
| 31 Oct 2023 | 0.51% | 3.66 | |
| 15 Nov 2023 | 0.47% | 3.42 | |
| 30 Nov 2023 | 0.33% | 1.00 | results (8-K) |
| 15 Dec 2023 | 0.14% | 1.00 | 10-Q filed |
See also: Virpax Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.